Impact of Antioxidant Treatment on DNA Fragmentation Index (Androferti)
Primary Purpose
Male Infertility
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Androferti
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Male Infertility focused on measuring sperm DNA strand breaks, antioxidants
Eligibility Criteria
Inclusion Criteria:
- Referred due to infertility
- Age: 18-50 years,
- Non-smoking,
- Sperm DNA Fragmentation Index >25%
Exclusion Criteria:
- Body mass index (BMI) ≥30,
- FSH outside the normal range of 2-8 IU/L,g)
- LH outside the normal range of 2-10 IU/L,
- T < 10nmol/L
- Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
- History of anabolic steroids use,
- Taking antioxidant supplementation the last six months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Antioxidant
Placebo
Arm Description
Androferti - 1 twice per day
Placebo - 1 twice per day
Outcomes
Primary Outcome Measures
DFI_3
3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin
DFI_6
6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay
Secondary Outcome Measures
Concentration_3
Change sperm concentration 3 months
Concentration_6
Change sperm concentration 6 months
Motility_3
Change sperm motility 3 months
Motility_6
Change sperm motility 6 months
Morphology_3
Change sperm morphology 3 months
Morphology_6
Change sperm morphology 6 months
Full Information
NCT ID
NCT03466229
First Posted
March 4, 2018
Last Updated
March 14, 2018
Sponsor
Region Skane
Collaborators
Q-Pharma, Octean
1. Study Identification
Unique Protocol Identification Number
NCT03466229
Brief Title
Impact of Antioxidant Treatment on DNA Fragmentation Index
Acronym
Androferti
Official Title
Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
July 1, 2015 (Actual)
Primary Completion Date
December 31, 2016 (Actual)
Study Completion Date
December 31, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Region Skane
Collaborators
Q-Pharma, Octean
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.
Detailed Description
In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.
Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.
Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient ~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.
The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.
Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.
The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .
The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Male Infertility
Keywords
sperm DNA strand breaks, antioxidants
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Double blind randomised placebo controlled study
Masking
Investigator
Masking Description
The active compound and placebo are given a number and the list linking this number to the type of preparation (placebo or active compound) is stored by one of the sponsors (Octean)
Allocation
Randomized
Enrollment
79 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Antioxidant
Arm Type
Active Comparator
Arm Description
Androferti - 1 twice per day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo - 1 twice per day
Intervention Type
Dietary Supplement
Intervention Name(s)
Androferti
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
DFI_3
Description
3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin
Time Frame
Change in DNA Fragmentation Index from Baseline to 3 months
Title
DFI_6
Description
6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay
Time Frame
Change in DNA Fragmentation Index from Baseline to 6 months
Secondary Outcome Measure Information:
Title
Concentration_3
Description
Change sperm concentration 3 months
Time Frame
Change in sperm concentration from baseline to 3 months in millions/mL
Title
Concentration_6
Description
Change sperm concentration 6 months
Time Frame
Change in sperm concentration from baseline to 6 months in millions/mL
Title
Motility_3
Description
Change sperm motility 3 months
Time Frame
Change in sperm motility from baseline to 3 months in %
Title
Motility_6
Description
Change sperm motility 6 months
Time Frame
Change in sperm motility from baseline to 6 months in %
Title
Morphology_3
Description
Change sperm morphology 3 months
Time Frame
Change in sperm morphology from baseline to 3 months in %
Title
Morphology_6
Description
Change sperm morphology 6 months
Time Frame
Change in sperm morphology from baseline to 6 months in %
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Men able to deliver semen sample and investigated due to infertility
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Referred due to infertility
Age: 18-50 years,
Non-smoking,
Sperm DNA Fragmentation Index >25%
Exclusion Criteria:
Body mass index (BMI) ≥30,
FSH outside the normal range of 2-8 IU/L,g)
LH outside the normal range of 2-10 IU/L,
T < 10nmol/L
Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
History of anabolic steroids use,
Taking antioxidant supplementation the last six months.
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
Plan to share IPD has not yet been discussed
Citations:
PubMed Identifier
30298673
Citation
Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology. 2018 Nov;6(6):811-816. doi: 10.1111/andr.12547. Epub 2018 Oct 8.
Results Reference
derived
Learn more about this trial
Impact of Antioxidant Treatment on DNA Fragmentation Index
We'll reach out to this number within 24 hrs